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Under the newly passed Leahy-Smith America Invents Act (AIA), the U.S. Patent and Trademark Office may
hear new challenges to stem cell patents. Here, we explore how the new law affects challenges to stem cell
patents, focusing on two recent cases, and discuss the future of stem cell patent disputes.Introduction
Stem-cell-related patents have long been
at the center of controversy. Religious
groups, patent lawyers, and even other
scientists have criticized the process of
claiming ownership over the most funda-
mental of biological building blocks
(Golden, 2010). Nonetheless, true legal
challenges to the validity or enforceability
of many stem cell patents remain rare and
are often limited to a narrow subset of cur-
rent licensees (Plomer et al., 2008). Newly
developed administrative procedures at
the U.S. Patent and Trademark Office
(PTO), however, may change this calcu-
lus. Under the Leahy-Smith America In-
vents Act (AIA), which has been in effect
since 2012, the PTO may now hear
several types of new challenges to both
pending patent applications and already
issued patents. These new administrative
procedures may be filed by anyone,
regardless of the person’s legal interest
in the patent. This shift may open the
door to more frequent—and aggres-
sive—patent challenges by disparate
stakeholders against stem cell patents.
Interestingly, two recent failed disputes,
BioGatekeeper Inc. v. Kyoto University
and Consumer Watchdog v. WARF, illus-
trate the possibilities—and limits—of this
legal development in stem cell patenting.
In this Forum, we explore the past state
of affairs in stem cell patents, the changes
wrought by the AIA (as illustrated by the
BioGatekeeper and Consumer Watchdog
suits), and the likely future for the security
of stem cell patents.
Patent Challenges at the PTO
before the AIA
Procedurally, patent disputes typically
proceed along one of two paths. The first
uses the federal court system to challenge
the validity of issued patents. As a matterof constitutional law, all federal court
cases must possess an ‘‘actual case or
controversy:’’ ‘‘that the dispute be ‘defi-
nite and concrete, touching the legal rela-
tions of parties having adverse legal inter-
ests’’’ (MedImmune, Inc. v. Genentech,
Inc., 2007). Practically, this means either
that the patent holder would first sue an
accused infringer directly or that the pat-
ent holder would threaten the infringer
with a suit such that, for legal purposes,
there exists a ‘‘substantial controversy’’
between the parties. The corollary to this
maxim, however, is that outsiders who
do not live under the threat of being
sued have no right to challenge the
validity of the patent in federal court.
Thus, at least prior to the AIA, chal-
lenging the validity of a patent or patent
application in federal court was generally
limited to those who had a direct, legal in-
terest in the patent: inventors who had
beenwrongfully left off of the patent appli-
cation, competitors who had pending
patent applications, licensees of the
patented technology, or users who had
been sued for infringement (Plomer
et al., 2008).
The second pathway involves the PTO.
Prior to the AIA, several administrative
procedures allowed a variety of parties
to request that the PTO reconsider pat-
ents already issued by the agency. One
such procedure, ‘‘inter partes reexamina-
tion’’—available since 1999—allowed
any person, at any time, to petition the
PTO to reconsider the patent in light of
new scientific or technical references
that cast doubt on the patent’s validity
(Tindell, 2007). At the same time, the
petitioner was limited to challenging the
patent’s validity on those references—
and not for other technical defects in
the patent document. In response, the
patent holder could alter its patent’sCell Stem Ceclaims at any time to avoid—or delay—
further proceedings. Usually, inter partes
reexamination functioned as a dispute
resolution mechanism for parties with a
direct interest in a particular patent:
over 75% of all inter partes reexamina-
tion requests ever filed concerned pat-
ents concurrently being litigated by the
same parties in federal court. Further-
more, relative to the pace of federal
litigation, disputes tended to drag on,
taking 3 years, on average, for the PTO
to decide a reexamination proceeding
(Love and Ambwani, 2014).
These limits on challenging patents,
combined with a robust licensing market,
led stem cell patents to be infrequently
challenged prior to the AIA (Roberts
et al., 2014). The few challenges that did
occur mostly concerned University of
Wisconsin professor James Thomson’s
broad, pioneering human embryonic
stem cell (hESC) patents (Plomer et al.,
2008). There, several prominent scien-
tists objected to the Wisconsin Alumni
Research Foundation’s (WARF’s) aggres-
sive licensing and enforcement strate-
gies. These scientists joined the legal
advocacy group The Foundation for
Taxpayer and Consumer Rights (now
called Consumer Watchdog) to challenge
James Thomson’s foundational human
embryonic stem cell patents before the
PTO. Nonetheless, such challenges re-
mained rare. The torpid pace of the inter
partes reexaminations further discour-
aged stem cell inventors from petitioning
the PTO to challenge their competitors’
patents; advances in the field would likely
eclipse the patented technology before
the PTO completed its proceedings
(Iancu and Haber, 2012). Therefore,
stem-cell-related patents remained rela-
tively safe from challenges until the pas-
sage of the AIA.ll 16, May 7, 2015 ª2015 Elsevier Inc. 461
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TheAIAmayhavechanged thingsdramat-
ically. Although it left the requirements for
federal litigation largely intact, the Act
substantially altered the administrative
procedures available to the public to
challenge patents at the PTO. First, and
foremost, the AIA revamped the old
system of inter partes reexamination into
a new system of inter partes review.
Rather than utilizing an ‘‘amendment and
response’’ procedure that accounted for
much of the old system’s delay, the new
system proceeds in a quick, trial-type
fashion that gives the PTO authority to
cancel all of a patent’s claims in their
entirety. In addition, multiple parties—
including members of the public with no
legal interest in the patent—may join in
the action at the discretion of the PTO.
And,while the filing fee for instituting an in-
ter partes review is high—to date, at least
$27,500—attorneys’ fees for inter partes
reviews often cost less than one-tenth
of traditional, federal court patent litigation
(http://www.mintz.com/newsletter/2014/
Advisories/4363-1014-NAT-IP/). Thepro-
ceedings also take half the time, roughly
15 months from start to finish. Inter partes
reviews are also legally easy to initiate
and, so far, have been very successful, in-
validating over 70% of the patent claims
adjudicated at the PTO (Love and Amb-
wani, 2014).
In addition, anyone may now challenge
patents currently before the PTO in what
are known as ‘‘preissuance submis-
sions.’’ Like the prior system of inter
partes reexamination, preissuance sub-
missions allow a third party to submit prior
published technical literature useful in
assessing—or challenging—the validity
of the contested patent, along with a
concise description of how the submitted
references cast doubt on the patent as
written. In contrast to the fee for inter
partes reviews, the fees for preissuance
submissions are quite cheap: several
hundred dollars, depending on the num-
ber of references included by the chal-
lenger (Iancu and Haber, 2012). Several
other administrative challenges have
also been created by the AIA—such as
covered business method reviews—but
it is unlikely that they will greatly affect
stem cell patents.
In any event, the AIA’s new administra-
tive procedures have been successful
insofar as they have allowed greater,462 Cell Stem Cell 16, May 7, 2015 ª2015 Elfaster participation by expanding the
criteria for filing trial-type challenges
beyond those who are directly threat-
ened by enforcement. So far, more inter
partes reviews have been filed since the
AIA took effect in 2012 than all of the in-
ter partes reexaminations from 1999–
2012. The PTO now also receives, on
average, roughly 70 preissuance submis-
sions each month (http://www.law360.
com/articles/581512/trends-from-2-years-
of-aia-post-grant-proceedings). These
numbers appear likely to increase as
practitioners become comfortable with
the new procedures.
The Consumer Watchdog and
BioGatekeeper Challenges
The ease and popularity of administrative
patent challenges after the AIA have
affected some of the more prominent
stem cell technologies. After Consumer
Watchdog lost its challenge to WARF’s
stem cell patents before the PTO, the or-
ganization appealed the decision to fed-
eral court. There, it asked the U.S. Court
of Appeals for the Federal Circuit to apply
the U.S. Supreme Court’s recent decision
on gene patenting, Association for Molec-
ular Pathology v. Myriad Genetics, Inc. In
Myriad, a unanimous Supreme Court
held that ‘‘naturally occurring’’ DNA seg-
ments were not patent eligible, even
though they had been ‘‘isolated’’ from
the surrounding chromosome (Kessel-
heim et al., 2013). Consumer Watchdog
argued that WARF’s patents claimed
that stem cells were analogous to the iso-
lated DNA segments in Myriad because
their properties are found in all embryonic
stem cells, including their naturally exist-
ing counterparts.
But, in its June 2014 decision, the Fed-
eral Circuit did not address the substance
of Consumer Watchdog’s challenge.
Rather, it held that because all federal
court challenges of patents—even those
stemming from the freely open, inter
partes review process—required an
‘‘actual case or controversy,’’ Consumer
Watchdog did not have standing to ap-
peal the PTO’s decision. Because WARF
never sued or threatened to sue Con-
sumer Watchdog itself, the group had no
standing to appeal the PTO’s decision; it
had suffered no legally apparent injury
related to the patent.
Not to be deterred, the group took
its fight to the Supreme Court. In itssevier Inc.petition last October, it argued that it
should not have to meet the typical
standing requirements to bring a case
in federal court because the AIA
expressly gives it, and other third parties,
the right to appeal the PTO’s decision.
Despite these arguments, the Supreme
Court announced this February that it
was declining to revisit the Federal Cir-
cuit’s decision.
Consumer Watchdog’s aggressive-
ness teaches an important lesson about
the future of patent challenges on
controversial technologies like stem
cells. At first glance, Consumer Watch-
dog’s fight against a patent that expires
in 2015 would seem puzzling. The scien-
tist-licensees that were named on the
original reexamination challenges drop-
ped off the case before the PTO’s 2012
decision. These individuals, whether
motivated by money or by an appeal to
public fairness, were either satisfied
that the reexaminations did the work of
limiting Thomson’s claims, settled with
WARF privately, or simply felt it was
time to move on. That left Consumer
Watchdog with no real financial dog in
the fight, other than an appeal to public
policy.
But the concern with public access
to promising technologies may motivate
future attorneys to take up mantles
against more stem cell patents, collabo-
rating with publicly minded researchers
as petitioners, just as with the Myriad
case. In this way, the future of patent
challenges may increasingly be at the
hands of special interest, anti-patent
groups and scientists, rather than
spurned licensees.
Not all new stem cell patent disputes
are so public-minded, however. As in
the early days of the WARF challenge,
the BioGatekeeper case appears to
have those with financial interests chal-
lenging induced pluripotent stem cell
(iPSC) patents. Currently an unknown
entity, BioGatekeeper, Inc. filed an inter
partes review against one of Nobel Prize
winner Shinya Yamanaka’s foundational
iPSC patents. Like the Consumer
Watchdog challenge, the BioGatekeeper
challenge invokes obviousness: that the
cellular reprogramming discovery was
based on pre-existing art, publications,
and patents that predate the Yamanaka
filings (Simon et al., 2010). In this case,
the prior art belongs to Rudolf Jaenisch,
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head Institute.
Although the PTO ultimately declined
to institute BioGatekeeper’s challenge,
the case stands as an example of how
patent challenges become easier—
and cheaper—to initiate after the pas-
sage of the AIA. There appear to be
multiple motivations driving the low
threshold use of the AIA. Analysts esti-
mate that total global revenues for com-
panies that supply iPSC research prod-
ucts will exceed $1 billion by 2015
(BioInformant Worldwide, 2014). The first
clinical study involving the transplanta-
tion of iPSCs into humans began re-
cruiting patients in August 2013. This
safety study will use iPSC-derived retinal
pigment epithelium to restore vision in
patients with wet age-related macular
degeneration, possibly addressing a
large unmet medical need. The spoils
of the market are being fought for among
a highly fragmented group of dozens
of patent holders, a third of which are
corporate affiliated (Roberts et al.,
2014). Thus, the AIA may provide
a way for hungry market entrants to
challenge patents on older, foundational
research without the standing require-
ments present in the Consumer
Watchdog suit.
The Future of Stem Cell Patents
after the AIA
As the Consumer Watchdog and Bio-
Gatekeeper challenges illustrate, the AIA
has provided broader avenues for third
parties to challenge stem cell patents
before the PTO. Although these proce-
dures still possess limits, these cases do
not appear to be isolated incidents.
Rather, three facets of stem-cell-related
patents in particular suggest that such ex-
changes are likely to become more
frequent in the future.
First, there is good reason to believe
that the robust licensing market that
generated such peace among stem
cell patent holders will not last forever.
A recent study suggests that the
biggest threat to the commercialization
of iPSCs is ‘‘the potential formation of
a patent thicket and mismanaged
licensing practices in a field that has
begun to privatize at an early preclinical
phase’’ (Roberts et al., 2014). Given
the rapid transfer of stem-cell patents
from the public to the private sector,this threat is quite real. As such, the
AIA seems to encourage commercial en-
terprises and inventors to file patent
challenges early and often to stave off
future competition or gain entry to the
market.
Second, as stem cell biotech com-
panies grow and become publicly traded,
they increasingly become attractive tar-
gets for hedge funds seeking to take short
positions. The AIA’s new procedures
allow short investors—as ‘‘non-interested
parties’’—to simultaneously challenge
their target’s patents at the PTOwhile tak-
ing a short equity position in the hopes
of either profiting on the challenge’s
downturn or receiving a settlement pay-
ment. Indeed, this is precisely the strategy
recently implemented by Dallas-based
Hayman Capital in the pharmaceutical
context. In February 2015, Hayman
Capital filed its first inter partes chal-
lenge, against Acorda Therapeutics’
patent on Ampyra, a multiple sclerosis
drug (http://www.reuters.com/article/2015/
01/07/pharmaceuticals-haymancapital-
idUSL3N0UM42O20150107). As of April
2015, it has filed four more challenges. To
the extent Hayman is successful, it
may cause other stem-cell IP investors,
like BioGatekeeper, to file additional
challenges.
Lastly, the new system of inter partes
review allows competing inventors and
frustrated researchers a fast and cheap
way to challenge patents—or to demand
royalty-free licensing or academic credit.
In addition, given the fractious history of
stem cell research, groups that object to
patenting on moral grounds—such as op-
position to patenting forms of life—could
deploy the AIA as a low-cost way to delay
or derail the commercialization of new
discoveries. Given the heated and very
public priority disputes simmering in the
stem cell field, this may remain more
than a distant possibility in some extreme
cases.
Whether the availability of new ave-
nues to challenge patents means solu-
tions or problems to stem cell patenting
depends on the reader’s point of view as
to the propriety of stem cell patents
in the first instance. As problems, the
answer to fixing them lies in maintain-
ing the robust licensing market that
currently exists for many stem cell pat-
ents. As long as licensable patents are
affordable, competitors will likely payCell Stem Cefor certainty rather than a roll of the
dice at the PTO. As solutions, time
will tell whether the AIA ultimately has
its intended effect of making it cheaper
and easier to weed out bad patents
before they wend their way into federal
court.
Conclusions
Stem-cell-related patents have enjoyed
a relatively stable existence since they
began to be issued in the early 1990s.
Much of that can be attributed to the
robust licensing market for the underlying
technologies and because few legal ave-
nues existed for third parties to cheaply
and effectively challenge overbroad or
invalid stem cell patents. The AIA and
the commercial development of new
stem cell technologies may upset this bal-
ance. Although still constrained by
limits—as demonstrated by the Con-
sumer Watchdog and BioGatekeeper
cases—new administrative procedures
before the PTO make it substantially
easier (and cheaper) to challenge stem
cell patents as they become issued. This
may be a natural stage in the life cycle of
any rapidly developing area of law and
technology.
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